Abstract Depression affects about 40 % of people with coronary heart disease (CHD). This group with depression and CHD have increased mortality and morbidity, worse healthrelated quality of life, use health services more frequently and consequently cost the health service and the national economy considerably more than their non-depressed counterparts. A number of characteristics of depression and plausible mechanisms have been proposed to explain this observed association, which could lead to improved understanding of the association and lead to new interventions to improve cardiac outcomes. This review summarises the evidence linking depression with worse cardiac outcomes, considers specific aspects of depression which may predict worse outcomes and reviews the mechanisms that could potentially explain the direct or indirect association of depression with coronary outcomes.
Introduction
Major depressive disorder affects about 20 % of people with coronary heart disease (CHD), and a similar proportion of people have increased symptoms of depression that make them feel unwell, but which fail to meet diagnostic criteria for major depressive disorder. Taken together, this approximate 40 % of people with CHD who also suffer from some form of depression are an important group as they have worse physical health outcomes associated with their CHD compared to similar patients without depression.
Mortality and Morbidity
A recent meta-analysis identified 34 cohort studies of people with a variety of CHD diagnoses in whom depression had been assessed and subsequent mortality (all cause or cardiac) had been determined over a mean follow-up period of 3 years [1] . Pooled effects from the 11 studies that controlled for the potentially confounding effect of severity of the underlying CHD showed that CHD patients with depression were 1.6 times more likely to die during follow-up that those who were not depressed. There was a suggestion that the risks associated with depression might be marginally greater in those following acute myocardial infarction (MI), compared to those with coronary artery bypass graft (CABG) (adjusted RR=1.67 vs 1.5). There was also a trend for the effects of depression on mortality among people following MI to be diminishing over time; OR=3.2 vs 2.0, p=0.08 for studies conducted before and after 1992, respectively [2] . This trend for the effects of depression on mortality to diminish could reflect the improvement in survival following MI, rather than improved treatment of depression in these populations.
Van Melle et al. conducted a systematic review and metaanalysis and identified nine studies of people following MI that examined the association of depression with subsequent cardiovascular events [2] . Pooled results showed that people
Health Service Utilisation
Depressed CHD patients are more likely to have cardiac-related hospital admissions [5, 6] , and more likely to attend the emergency department [7, 8] , though these findings have not been entirely consistent across studies [9] . In one systematic review, depressed CHD patients were 50 % more likely to have an episode of unscheduled care than non-depressed [10] . Depression was associated with subsequent urgent hospitalisation in the one study that controlled for severity of underlying heart disease (whether the MI was anterior, HR= 1.4).
The healthcare costs for depressed CHD patients are higher than that of the non-depressed. From a study of 848 people who survived for 12 months following admission for acute MI, the 260 with depression had direct healthcare costs 41 % higher than the non-depressed, due to increased outpatient costs, more emergency department visits and longer cardiac readmissions [7] . Among 654 women with suspected CHD, those with mild to moderate depression (n=292) had 33 % 5-year higher costs of cardiovascular care and 21 % higher medication costs [11] .
Total societal costs may also be increased among depressed CHD patients, due to lost of productivity arising from delayed return to work. In a systematic review of the literature, O'Neil et al. found that depression at baseline predicted reduced return to work 6 to 12 months after acute coronary syndrome (7 out of 12 studies) [12] . The findings were mixed for past history of depression, with one study showing an association between past depression and subsequent return to work, and one study finding no such association.
Characteristics of Depression Associated with Poor Cardiac Outcomes
Substantial research has investigated specific characteristics of depression that are predictive of worse outcomes among people with CHD. This important line of research has potential to clarify mechanisms by which depression may cause worse medical outcomes, may help identify subgroups of individuals at particularly high risk of poor outcome and may even identify novel targets for intervention to improve cardiac and depression outcomes.
The characteristics that have received most interest include (a) the severity of depression, (b) the timing of onset, (c) the symptom profile and (d) the treatment responsiveness of depression.
Severity of Depression
If depression causes poor cardiac outcomes, it should be expected that people with more severe depression would be at particularly increased risk of adverse outcomes. Meta analyses that have examined this question have shown conflicting findings, however. Nicholson et al. did not find that studies recruiting people with clinical depression (i.e. determined using diagnostic interview or whether individual was taking drug treatment for depression) showed a stronger association with poor cardiac outcomes than studies recruiting patients using depressive symptom scales [1] . This latter group would include people who did not reach diagnostic criteria for clinical depression, so on average could be considered to have less severe depression. In fact, they found that studies identifying depression using depression symptoms scales had larger effects than studies using clinical depression assessments (RR= 1.9 vs 1.3, respectively), which is counter-intuitive. Furthermore, there was no trend to suggest that studies identifying lower prevalences of depression (which could indicate a higher threshold for depression) had higher mortality. The majority of studies contributing to these pooled results had not adjusted for key covariates however, which may have influenced this finding. An earlier meta-analysis did show a dose: response effect, with a greater effect for people with more severe clinical depression as opposed to people with depressive symptoms (OR=2.6 vs 1.8, respectively), though this effect only became apparent in the subgroup of studies with follow-up over 2 years [13] . So on balance, it remains unclear whether severity of depression influences cardiac outcomes.
Timing of Onset of Depression
Findings from a number of studies have indicated that the timing of the onset of the episode of depression, with regards to the index cardiac event, may be important in predicting worse outcomes among people with CHD. In particular, a number of prospective cohort studies of patients admitted to hospital following acute coronary syndrome seem to indicate that it is depression in the period following acute coronary syndrome as opposed to depression that pre-dated acute coronary syndrome that was linked to adverse cardiac outcomes [14] [15] [16] [17] . As with the findings related to the severity of depression, these findings are counter-intuitive. People with depression that pre-dated their acute coronary syndrome would be likely to include people who were more socioeconomically disadvantaged, experiencing multiple chronic life stresses and difficulties, with more severe and long-lasting depression. Furthermore, not all studies support the findings that depression in the post-acute coronary syndrome period alone predicts greater risk of cardiac mortality and morbidity; a number of studies have found that people with a history of past depression are also at increased risk [18, 19] .
In a systematic review, Leung et al. identified 13 studies that examined the timing of the onset of depression relative to the onset of the CHD, and found that, compared to people who reported never experiencing depression, risks of poor outcomes (all-cause mortality, cardiac mortality or cardiac morbidity) were increased both among individuals whose first episode of depression started after the onset of CHD (RR= 2.11), and among those whose depression was a recurrence of previous depression (RR=1.59) [20•]. Among people with a history of previous depression but with no depression following onset of CHD, risk was reduced (RR=0.79). This review indicates that risk of poor outcomes is increased among all patients with depression in the post MI period, but that the outcomes might be particularly poor among people who develop their first episode of depression after the onset of their CHD.
Symptom Profile of Depression
Four studies have indicated that somatic symptoms of depression (such as fatigue, insomnia, loss of appetite and somatic pre-occupation), identified by factor analysis of the Beck Depression Inventory, predicted subsequent cardiovascular mortality, even after controlling for markers of severity of cardiac disease, whereas cognitive symptoms did not [21] [22] [23] [24] . Doyle et al. used symptoms scales derived from multiple measures and confirmed that symptoms of fatiguesadness (i.e. somatic symptoms) predicted subsequent major cardiac events (hazards ratio=1.8), but other symptoms dimension did not [25] .
Results from two other studies that selected somatic symptoms from the nine-item version of the Patient Health Questionnaire (PHQ-9) are not entirely consistent with these findings, however. One study showed that somatic symptoms of depression predicted subsequent hospitalisation after MI but not mortality, whereas cognitive symptoms predicted neither [26] . Another showed that somatic symptoms predicted subsequent cardiovascular events among people with stable CHD, after controlling for other cardiac risk factors [27] . Furthermore, a number of studies have also shown that cognitive symptoms can also predict cardiac outcomes among people with cardiac disease [28, 29] . So, whilst there is a suggestion that somatic symptoms of depression might be more strongly predictive of adverse cardiac outcomes, results from studies are inconsistent and unconvincing. Differences in the depression scales used and the way somatic symptom dimensions are identified are likely to contribute to this heterogeneity among study findings. Controlling for different covariates is likely to influence the magnitude of the observed associations. Also, somatic symptoms are likely to partly reflect the severity of underlying cardiac disease, the presence of comorbid medical conditions and the treatments used, and the association with cardiac prognosis may be confounded by any of these factors. Further research is needed to clarify the importance of specific symptom dimensions.
Treatment Responsiveness of Depression
Among people with depression who receive antidepressants, a significant proportion of people will fail to respond to antidepressant therapy. Rate of non-response among those treated with antidepressants have ranged between 19 and 34 % [30] . Whilst no depression treatment trial among patients with CHD has demonstrated that a reduction in depression leads to improvement in cardiac survival, secondary analyses of data from a number of trials have indicated that people who respond well to the depression treatment have better cardiac outcomes than those who fail to respond to depression treatments.
Secondary analyses from the ENRICHD study [19] , in which post myocardial infarction patients with depression and/or low perceived psychosocial support were treated with a psychological intervention with or without an antidepressant have shown this. People whose depression got worse on treatment were more likely to die compared to people whose depression remain unchanged (RR=1.6) and people whose depression improved (RR=2.5) [31] . Using different criteria to identify treatment-resistant depression (<50 % reduction in depression score or still having significant symptoms after 6 months), Banankhah et al. performed further analysis of ENRICHD trial data and found that people with treatmentresistant depression had almost twice the mortality of people without treatment resistant depression [32] . Re-analyses of data from the MIND-IT trial and the SADHART trial of antidepressants in patients with recent MI showed similar findings. De Jonge et al. showed non-responders experienced more cardiac events (mortality or cardiac hospitalisation) than treatment responders (26.2 vs 7.4 %) [33] . Glassman et al. found that at long-term follow-up, patients from the treatment and the placebo arms who had shown minimal improvement in depression had the highest mortality compared to those who showed most improvements in depression (adjusted hazards ratio=1.8) [34] .
It must be recognised that such secondary subgroup analyses are vulnerable to the effects of confounding, however. Underlying differences between responders and nonresponders (i.e. apart from their response to treatment) may account for the observed associations of depression with cardiac mortality and morbidity. Those differences if identified can be controlled for in multivariable analyses, though that does not guarantee that the confounding effect is completely removed (i.e. residual confounding). Furthermore, differences that are unmeasured and unknown may also account for the observed associations. As such, the observations that depression that is resistant to depression predicts worse cardiac outcome must be interpreted with extreme caution.
In summary, whilst this important line of research has potential to clarify mechanisms of association between depression and cardiac outcomes, to identify people who are particularly high risk and thereby facilitate targeting and possibly development of interventions, the findings to date have not convincingly identified any specific characteristics of depression that predicts adverse cardiac outcomes.
Mechanisms Underpinning the Association Between Depression and Worse Cardiac Outcomes in People with Coronary Heart Disease
A considerable research literature has developed around potential mechanisms that could explain a causal association between depression and subsequent medical outcomes among people with coronary heart disease. Many studies have considered single causal pathways to explain the observed associations between depression and poor cardiac outcomes, though there is increasing recognition that many (if not all) of these pathways are interlinked, and no single pathway is likely to explain the observed effects of depression. Stapelberg et al. conducted a thorough review of the literature with the intention of creating a topography of causal mechanisms that potentially link depression and cardiac disease [35] . They identified six domains of causal mechanism:
(a) Behavioural mechanisms (b) Genetic mechanisms (c) Inflammatory mechanisms (d) Endothelial dysfunction and platelet activation (e) Polyunsaturated omega-3 free fatty acid deficiency (f) Hypothalamic-pituitary-adrenal axis (HPA) and autonomic mechanisms.
Behavioural Mechanisms
Among individuals with CHD, depression has been shown to be associated with a number of behavioural and lifestyle factors that are also recognised risks for poor cardiac outcomes including:
(i) Smoking: depression is associated with twice the risk of being a current smoker [36] [37] [38] , and chances of discontinuing smoking are reduced by 40 % [39] . (ii) Poor diet: depression is associated with increased risk of obesity [40, 41] (particularly visceral obesity [42] ), low vegetable and fibre intake [42] and increased risk for the development of type 2 diabetes [43, 44] . (iii) Reduced exercise/physical activity: depression is associated with double the risk of low levels of physical activity and sedentary lifestyle [37, 38, [45] [46] [47] [48] and reduced capacity for physical exercise [41] . In a study of 1017 outpatients with stable CHD, Whooley et al. found that physical activity partially mediated the effects of baseline depression on subsequent cardiovascular events [37] . (iv) Poor adherence to treatment recommendations: depression is associated with reduced adherence to prescribed medication as determined by self-report [37, 49] and electronic monitoring of medication [50, 51•] . In a study of patients with recent acute coronary syndrome, Rieckmann et al. showed that the adverse effects of depressive symptoms on subsequent cardiac events were reduced by approximately 30 % when compliance with aspirin at 1 week and 1 month was included in the regression analysis. This finding is consistent with the conclusion that aspirin adherence could partially mediate the observed association between depression and adverse cardiac outcomes [51• ] . Depression predicts poor attendance at cardiac reh a b i l i t a t i o n [ 5 2 ] a n d t w i c e t h e r i s k o f discontinuing cardiac rehabilitation once started [53] .
Reduced motivation, pessimism relating to potential benefits of treatment, loss of interest in self-care and impaired memory are all common features of depression and could contribute to increased risks associated with behavioural and lifestyle factors [54] .
Genetic Mechanisms
Genetic mechanisms could partly explain the observed association between depression and cardiac outcomes. Functional polymorphisms of 5HT transporter protein (5HTT) have been studied most extensively in this context. 5HTT is found in the walls of neurones, is responsible for the re-uptake of 5HT that has been released into the synaptic cleft and is the site of action of specific serotonin re-uptake inhibitors (SSRIs) antidepressants. Functional polymorphisms of 5HTT result in alleles of different lengths. The short allele (S) is associated with reduced expression of 5HTT and a number of studies have shown links between the S allele and depression [55, 56] . The S allele is also linked to the occurrence of cardiac events such as cardiac death, revascularization, heart failure, re-infarction, arrhythmia and unstable angina [57] , though the exact mechanism by which this occurs is not clear. There is some evidence that the LS genotype may be linked to increased levels of cholesterol and triglycerides [58] . Genetic variations related to endothelial dysfunction and platelet aggregation may also predict depression and so explain the observed associations between depression and coronary heart disease outcomes [59] .
Inflammatory Mechanisms
Increased levels of inflammation and inflammatory cytokines are markers of risk for the development of coronary disease [60] , and predict poor cardiac outcomes among people with coronary heart disease [61] [62] [63] . There remains some uncertainty relating to the magnitude of this effect and the extent it can be attributed to low-quality studies and publication bias [64] .
It has been suggested that depression could be associated with worse cardiac outcomes by maintaining inflammatory responses once they have been initiated in people with coronary disease. Depression is associated with an increase in levels of biomarkers of inflammation, including c-reactive protein (CRP), interleukin 1 (IL-1) and interleukin 6 (IL-6) [65] . Epidemiological studies have demonstrated that this association is bidirectional [66, 67] . Experimental studies, in which inflammation is triggered by the administration of an endotoxin or attenuated vaccine, have demonstrated a transient increases in the symptoms of depression, compared to placebo, that was associated with increases in IL-1 receptor antagonist (IL-1Ra), IL-6 and tumour necrosis factor alpha (TNF-α) [68, 69] . Randomised controlled trials of TNF-α inhibitors which reduce inflammation in people with severe and chronic inflammatory conditions also improve depression [70] . Furthermore, administration of interferon alpha (IFN-α), which greatly increases the level of inflammatory mediators, is associated with development of major depression up to one third of patients [71] , which is preventable in many by pretreatment with antidepressants [72] . Reduction in the bioavailability of 5HT by inflammatory mediators via a number of mechanisms has been proposed to explain the association between inflammation and depression [73] .
A number of cross-sectional studies of individuals with acute and stable coronary heart disease have shown depression to be associated with increased levels of CRP [37, 74] , increased white cell count [75] , increased soluble intercellular adhesion molecule-1 [76] and also with reduced cortisol and reduced expression and sensitivity of glucocorticoid receptor [77] . In a study of 1017 outpatients with stable CHD, Whooley et al. found that CRP partially mediated the effects of baseline depression on subsequent cardiovascular events [37] . Not all studies have shown an association between depression and markers of inflammation among all people with established CHD, however [78] , possibly due to the anti-inflammatory actions of some cardiac medications [76] .
In the only prospective study of its nature to date, Steptoe et al. examined the association of markers of inflammation taken on the day following admission for 216 individuals after acute coronary syndrome, with depression 3 weeks and 6 months later [79] . White cell count on admission predicted (i) somatic symptoms of depression 3 weeks later among the subgroup of individuals with no prior history of depression only, and (ii) cognitive symptoms of depression and anxiety 6 months later in the whole population. CRP did not predict depression at either time point. These findings provide some support for the prospective association between inflammation following acute coronary syndrome and subsequent symptoms of depression and anxiety. The meaning of the differences in effect seen in those with and without a history of depression, and between somatic and cognitive symptoms of depression at different time points, remain unclear and require further study.
Endothelial Dysfunction and Platelet Activation
The impact of depression on subsequent cardiac outcomes could be mediated via endothelial dysfunction and increased platelet reactivity. Using fluorescence-activated flow cytometry, Musselman et al. were the first to show significantly increased platelet activation at rest and increased responsivity to a mild orthostatic challenge (standing from lying position), in depression compared with non-depressed individuals [80] . This observation was supported by the findings in a large community sample (n > 2000), in which people meeting criteria for depression had greater mean platelet volume (a correlate of platelet reactivity) than non-depressed, even after controlling for other medical and pharmacological factors that could influence platelet volume [81] . Beta-thromboglobulin and platelet factor-4 (measures of platelet reactivity) have been found to be higher among depressed outpatients with CHD, compared to non-depressed outpatients with CHD and healthy controls, which could not be explained by differences in age, sex or severity of cardiac disease [82] . People hospitalised following acute coronary syndrome who also had moderate depression (PHQ-9≥10) showed increased platelet aggregation in response to ADP than non-depressed controls [83] .
With regards to endothelial dysfunction, in a recent systematic review and meta-analysis, Cooper et al. identified 12 studies that examined the association of endothelial dysfunction (measured using flow mediated dilatation of the brachial artery), which used cross-sectional or retrospective design. A significant association between depression and endothelial dysfunction was found, though the effect size was small (r=0.19). Larger effects were seen in studies of high quality (r=0.29), among subjects with existing coronary artery disease or risk factors for CHD (r= 0.29), among subjects meeting criteria for major depressive disorder (as opposed to increased symptoms of depression only: r= 0.3 vs 0.13, respectively) and among subjects <55 years of age (r=0.35 vs 0.15, respectively) [84] .
Omega-3 Polyunsaturated Fatty Acids
The observed association between depression and CHD could be due to abnormalities in omega-3 fatty acid metabolism. Polyunsaturated omega-3 fatty acids have been linked to cardiovascular outcomes in a number of studies. Early studies showed that consumption of omega-3 fatty acids reduces progression of coronary disease and the risks of adverse cardiac outcomes, such as a cardiac arrest [85, 86] . Evidence from randomised controlled trial has been mixed, though the weight of evidence still supports the likely beneficial effects of omega-3 fatty acids on cardiac outcomes [87] .
Omega-3 fatty acids are important for neurotransmission and may influence depression via modulating effects on serotonin, dopamine and brain-derived neurotrophic factor function, and via effects on the HPA axis and inflammation [88] . Depression has been shown to be associated with reduced levels of omega-3 fatty acids in people with and without coronary disease [89, 90] . Meta analyses of randomised controlled trials have demonstrated that treatment with omega-3 fatty acids has been shown to improve depression [91] [92] [93] [94] , though the effects appear to be sensitive to the severity of depression (with more significant effects in people with more severe depression), and the relative proportions of eicosapentaenoic acid (EPA) to docosahexaenoic acid (DHA) (with doses containing >60 % EPA having most effect). Furthermore, the effects estimated in meta-analyses may be inflated by poor-quality trials and publication bias [95] .
Hypothalamic-Pituitary-Adrenal Axis and Autonomic Mechanisms
Depression is associated with a number of changes in functioning of the hypothalamic-pituitary-adrenal axis (HPA) and the autonomic nervous system that have also been shown to predict poor cardiac outcomes.
CRH release is increased in depression, resulting in increased activity of the HPA and autonomic nervous system, and changes in behaviour that are similar to those observed in response to stress [96] . The increase in plasma cortisol that results from increased CRH release has been shown to be associated with development of hypertension, diabetes and atherosclerosis, which could explain the association between depression and cardiac outcomes [97, 98] .
Increases in CRF are associated with increased sympathetic activity, resulting in increased heart rate and reduced heart rate variability, which have been shown to predict cardiac events (fatal and non-fatal) and sudden death among otherwise healthy individuals and those with prior cardiac disease [99, 100] . Depression is associated with reduced heart rate variability. In a study of 32 depressed individuals, those with severe depression showed reduced heart rate variability compared to nondepressed controls, with individuals categorised as having moderate depression showing an intermediate effect [101] . The same pattern has been found in people with cardiac disease. Among 38 patients with CHD, heart rate variability (SDNN) was significantly reduced among those with depression (n=19) compared to the non-depressed (n=19) [102] . Other measures of heart rate variability were reduced among the depressed group, though differences were not statistically significant. In secondary analysis of data from the ENRICHD study, mortality was found to be greatest among depressed post MI patients compared to nondepressed controls (HR=2.8), after controlling for other predictors of mortality (age, diabetes, LVEF, history of MI, Killip class, medications) [103] . This hazard ratio was reduced to 2.1, after controlling for heart rate variability (log very low frequency power), indicating that heart rate variability could, in part, mediate the observed association between depression and cardiac mortality. Not all studies have demonstrated that heart rate variability mediates the association between depression and subsequent cardiac outcomes, however [104] .
Similarly, some of the effects of depression may also be mediated through the parasympathetic nervous system. There is evidence, among people with and without cardiac disease, that depression is associated with reduced cardiac vagal control, which also predicts poor cardiac outcomes, including cardiac mortality [105] .
Conclusion
Depression is common in people with CHD, and observational studies have shown that it is associated with worse cardiac outcomes. The nature of the association (i.e. whether causal or not) remains unproven. No study has demonstrated improvement in cardiac outcomes following improvement in depression alone. It remains entirely possible that the association between depression and cardiac outcomes is confounded. The association between depression and subsequent cardiac outcomes has been shown to remain significant (though with reduced magnitude) after statistically controlling for recognised confounders, such as the severity of cardiac disease. Continued residual confounding remains a possibility, due to inadequate statistical control for recognised confounding factors or due to the effects of unrecognised confounders.
A number of studies have focused on the specific characteristics of depression that may particularly predict adverse cardiac outcomes. Such research could potentially increase our understanding of what it is about depression that specifically predicts worse outcomes and thereby clarify the mechanisms underpinning this observed association. Furthermore, such studies could identify which subgroups of individuals are at particularly high risk and worthy of specific additional intervention, leading to more personalised treatment. Some studies have shown positive findings though the literature is very mixed, with the result that it remains unclear whether specific aspects of depression predict adverse cardiac outcomes.
Whilst any causal relationship of depression with subsequent adverse cardiac outcomes has yet to be proved, a number of plausible behavioural and physiological mechanisms have been proposed, explaining how depression and cardiac outcomes may be associated directly or indirectly. Mediation analyses have shown that some of these behavioural and physiological factors could partially mediate the association between depression and adverse cardiac disease. No specific behavioural or physiological factor has been shown to convincingly account for a major proportion of the variance in the observed associations, however.
These multiple potential mechanisms are all interlinked in a complex network of causal pathways, though most studies have focused on single pathways or a couple of pathways at most. None of the proposed pathways are mutually exclusive. Many pathways may be active simultaneously. Some pathways may be more active in certain people with certain types of coronary disease or depending on the types of treatment taken. Consequently, it remains unclear which of these pathways are most important, how they interact in different people under different circumstances and how future interventions may target these pathways to improve cardiac outcomes. Future studies should consider a more comprehensive evaluation of the network of potential causal pathways linking depression and CHD outcomes, to examine how they interact in population with CHD and depression and to evaluate their relative importance.
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